These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

810 related articles for article (PubMed ID: 28222098)

  • 1. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
    Wu PY; Cheng CY; Liu CE; Lee YC; Yang CJ; Tsai MS; Cheng SH; Lin SP; Lin DY; Wang NC; Lee YC; Sun HY; Tang HJ; Hung CC
    PLoS One; 2017; 12(2):e0171596. PubMed ID: 28222098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
    Tseng YT; Yang CJ; Chang SY; Lin SW; Tsai MS; Liu WC; Wu PY; Su YC; Luo YZ; Yang SP; Hung CC; Chang SC
    Int J Infect Dis; 2014 Dec; 29():12-7. PubMed ID: 25312984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
    Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G;
    Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
    Peters PJ; Stringer J; McConnell MS; Kiarie J; Ratanasuwan W; Intalapaporn P; Potter D; Mutsotso W; Zulu I; Borkowf CB; Bolu O; Brooks JT; Weidle PJ
    HIV Med; 2010 Nov; 11(10):650-60. PubMed ID: 20659176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
    Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
    Mankhatitham W; Lueangniyomkul A; Manosuthi W
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):651-8. PubMed ID: 21706943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.
    Bussmann H; Wester CW; Thomas A; Novitsky V; Okezie R; Muzenda T; Gaolathe T; Ndwapi N; Mawoko N; Widenfelt E; Moyo S; Musonda R; Mine M; Makhema J; Moffat H; Essex M; Degruttola V; Marlink RG
    J Acquir Immune Defic Syndr; 2009 May; 51(1):37-46. PubMed ID: 19282782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of nevirapine-treated patients in a single-centre cohort.
    Colafigli M; Di Giambenedetto S; Bracciale L; Fanti I; Prosperi M; Cauda R; De Luca A
    HIV Med; 2009 Sep; 10(8):461-9. PubMed ID: 19459991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients.
    Van Welzen B; Mudrikova T; Arends J; Hoepelman A
    HIV Med; 2012 Aug; 13(7):448-52. PubMed ID: 22413955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
    Manfredi R; Calza L; Chiodo F
    HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
    Martínez E; Blanco JL; Arnaiz JA; Pérez-Cuevas JB; Mocroft A; Cruceta A; Marcos MA; Milinkovic A; García-Viejo MA; Mallolas J; Carné X; Phillips A; Gatell JM
    AIDS; 2001 Jul; 15(10):1261-8. PubMed ID: 11426070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
    Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
    Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
    Mocroft A; Phillips AN; Ledergerber B; Smith C; Bogner JR; Lacombe K; Wiercinska-Drapalo A; Reiss P; Kirk O; Lundgren JD;
    Antivir Ther; 2010; 15(4):563-70. PubMed ID: 20587849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
    Wit FW; Kesselring AM; Gras L; Richter C; van der Ende ME; Brinkman K; Lange JM; de Wolf F; Reiss P
    Clin Infect Dis; 2008 Mar; 46(6):933-40. PubMed ID: 18271750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up.
    Lin KY; Cheng CY; Li CW; Yang CJ; Tsai MS; Liu CE; Lee YT; Tang HJ; Wang NC; Lin TY; Lee YC; Lin SP; Huang YS; Zhang JY; Ko WC; Cheng SH; Hung CC;
    PLoS One; 2017; 12(6):e0179870. PubMed ID: 28665938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
    Snijdewind IJ; Smit C; Godfried MH; Nellen JF; de Wolf F; Boer K; van der Ende ME
    J Infect; 2012 Apr; 64(4):409-16. PubMed ID: 22227465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.